Our model-based simulations indicate primary activation of the immune system, with a secondary tumor-driven influx of immunosuppressive components (ISC) as well as triggering intrinsic factors that limit anti-tumor efficacy of the immune response (e.g., PD-(L)1), in all three syngeneic models tested (CT26, MC38, MCA205). The gene discussed is CD274; the disease is neoplasm.